Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05386615 · ClinicalTrials.gov registry record

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

A clinical trial of Uterine Fibroid, sponsored by InSightec.

Recruiting
Registry status
200
Enrollment target
6
Study locations

NCT05386615: Recruiting study of Uterine Fibroid, sponsored by InSightec.

NCT05386615 is a study of Uterine Fibroid that is actively recruiting participants, run by InSightec. The registered enrollment target is 200 participants, below the 282-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (29% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05386615, a study of Uterine Fibroid, is actively recruiting participants, sponsored by InSightec.

RECRUITING
Registry status
200 participants
Enrollment target
6
Study locations

Study Summary

The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.

Primary Outcome

All adverse events and/or serious adverse events will be documented and reported according to protocol.

Conditions Studied

Interventions

  • DEVICE Body System - Functional

Study Locations (6)

Other

  • Huashan Hospital Affiliated to Fudan University - Shanghai
  • Shanghai No. 1 Hospital - Shanghai
  • Shanghai No.1 Hospital - Shanghai

California

  • UCLA - Los Angeles
  • Stanford University - Stanford

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2016-02-16
Est. Completion 2026-12-31
InSightec

38 total trials

What NCT05386615 shows while recruiting

NCT05386615 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 282-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (29% lower).

The record links to 1 condition, with Uterine Fibroid appearing as the primary indexed condition, and to 1 intervention - of which Body System - Functional is the first listed.

NCT05386615 lists 6 locations in 3 states (Other, California, Minnesota).

Frequently Asked Questions

What is clinical trial NCT05386615 about?

NCT05386615 is a clinical study titled "Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids". The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.

What is the current status of trial NCT05386615?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2016-02-16. Estimated completion is 2026-12-31.

What conditions does trial NCT05386615 study?

This clinical trial studies the following conditions: Uterine Fibroid.

What interventions are being tested in trial NCT05386615?

The interventions under investigation include: Body System - Functional (DEVICE).

Who is sponsoring clinical trial NCT05386615?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05386615 being conducted?

This trial has 6 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Fibroid

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05386615, the US trial registry maintained by the National Library of Medicine. NCT05386615 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.